Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Viridian Therapeutics, Inc. (MGEN)
|
Add to portfolio |
|
|
|
| Price: |
$15.37
| | Metrics |
| OS: |
43.7
|
M
| |
-63
|
% ROE
|
| Market cap: |
$671
|
M
| |
-239
|
% ROIC
|
|
Net cash:
|
$490
|
M
| |
$11.21
|
per share
|
|
EV:
|
$182
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($210)
|
M
| |
|
|
|
EBIT
|
($211)
|
M
| |
|
|
| EPS |
($5.17)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-05-17 |
| Revenues | 1.8 | 3.0 | 1.1 | 4.5 | 8.4 | 8.4 | 4.0 | 19.6 |
| Revenue growth | -40.2% | 182.2% | -76.5% | -46.8% | 109.5% | -57.3% | 15.1% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 41.5 | 0.0 | 35.2 |
| Gross profit | 1.8 | 3.0 | 1.1 | 4.5 | 8.4 | -33.1 | 4.0 | -15.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -394.5% | 100.0% | -79.6% |
| Research and development | 100.9 | 56.9 | 28.3 | 34.8 | 30.4 | | 19.6 | |
| General and administrative | 35.2 | 25.8 | 13.3 | 11.6 | 11.0 | 11.0 | 10.9 | 10.9 |
| EBIT | -134.3 | -79.7 | -40.5 | -42.0 | -33.1 | -33.1 | -26.5 | -26.5 |
| EBIT margin | -7579.2% | -2690.8% | -3859.0% | -941.0% | -394.5% | -394.5% | -662.8% | -135.2% |
| Pre-tax income | -129.9 | -79.4 | -110.7 | -41.9 | -32.7 | -32.7 | -26.5 | -26.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -129.9 | -79.4 | -110.7 | -41.9 | -32.7 | -32.7 | -26.5 | -26.5 |
| Net margin | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -390.0% | -662.4% | -135.1% |
| |
| Diluted EPS | ($4.05) | ($6.66) | ($31.13) | ($20.04) | ($1.10) | ($1.10) | ($1.38) | $0.00 |
| Shares outstanding (diluted) | 32.1 | 11.9 | 3.6 | 2.1 | 29.6 | 29.6 | 19.2 | 19,244.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|